Acrivon Therapeutics (ACRV) said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation.
The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review for approvals.
Shares of Acrivon Therapeutics were up nearly 21% in recent Wednesay trading.
Price: 7.15, Change: +1.24, Percent Change: +20.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.